现阶段，伴随着中国房地产市场正式迈入存量时代，AIoT技术开始重构全屋智能生态，中国智能净水家电行业正经历一场前所未有的底层革命。在居民用水健康意识全面觉醒、消费持续向品质化/安全化升级的当下，传统净水行业深陷渗透率不足、产品同质化内卷、核心用户痛点长期未解的增长焦虑，而一场以技术创新为核心、场景适配为抓手的产业变革，正以前置过滤器为核心切口，全面改写全屋净水行业的竞争格局。随着新材料、物联网、智能控制技术与家庭用水场景深度融合，中国净水行业正开启以产品创新为核心的高质量发展新征程。 在此背景下，弗若斯特沙利文（Frost & Sullivan，以下简称“沙利文”）正式发布《2026年全球产品创新指数系列研究报告第3期：智能净水家电进化新路径，前置过滤器品类洞察》（以下简称“报告”），以全景视角拆解行业变革逻辑，指出在政策导向、产业升级、需求扩容、技术突破四重共振下，前置过滤器已从全屋净水系统的“边缘配件”升级为家庭用水安全的“核心入口”，从可选消费加速转变为城市家庭居住的刚需配置。以“反重力”前置过滤器、多合一前置过滤器、稳压防护型前置过滤器、全屋智能联动前置过滤器为代表的四大创新物种强势崛起，成为行业增长的全新核心引擎，中国净水行业正式迈入以技术创新为核心的价值竞争新时代。 微信扫码获取报告 01 品类升级：从过滤工具到用水中枢，重构全屋安全防线 本次报告聚焦净水行业四大核心创新品类，深度拆解当下极具价值的产品创新方向。净水赛道的“新物种”进化浪潮汹涌来袭，正彻底颠覆传统前置过滤器“单一过滤、被动防护、功能割裂、人工运维”的行业痛点，全面重塑为“技术驱动、全链路防护、主动智能、场景闭环”的全屋用水安全中枢。行业变革沿着技术、功能、场景、生态四大维度全面突破，加速推动前置过滤器跳出单一过滤工具定位，进阶为现代家庭不可或缺的用水基础设施，开启行业高质量发展新征程。 来源：沙利文分析   02 技术升级：从单点优化到底层重构 行业技术创新已从传统的参数微调转向底层逻辑与结构的系统性突破，形成四条清晰的主流技术路线，精准解决了长期制约行业发展的核心痛点。 在过滤技术领域，以"反重力"净污分离技术为代表的结构性创新实现了行业突破。该技术通过倒置水路设计，实现净水"反重力"上溯、污水向下分流的物理隔离效果，从根源上破解了“25μm高精度过滤与15T/h以上大通量不可兼得”的行业顽疾，同时大幅降低了滤网堵塞与二次污染风险。新锐品牌 韦思卡尔 凭借该技术实现赛道突围，其WSP-85-80T系列产品入围2026年 AWE艾普兰奖 ，并牵头参与中国家用电器协会相关行业团体标准起草。 来源：沙利文分析   03 用户需求：从基础饮水到全场景健康，免维护与智能化成刚需 居民用水健康需求发生了结构性升级，推动产品功能与用户体验持续迭代。 用户需求已从单一的直饮场景向全场景用水拓展。数据显示，除了95%的用户关注直饮安全外，烹饪煮饭（89%）、刷牙洗漱（53%）、家用电器用水（43%）等生活用水场景的需求渗透率显著提升，婴儿辅食制备、美容护肤、宠物植物养护等细分场景的定制化需求也快速增长。 “免维护、长效耐用”成为用户的核心诉求。消费者对人工运维操作的容忍度大幅降低，全自动定时冲洗、免换滤芯、长寿命滤网等功能成为购买决策的关键因素，能够显著降低用户长期使用成本与时间成本的产品更受市场青睐。 安全防护与智能体验需求显著升级。除了水质安全，用户对水路系统安全的关注度大幅提升，稳压抗水锤、防漏水、隔铅抑菌等安全功能从高端卖点变为中高端产品的标配。同时，随着全屋智能家装渗透率的提升，能够接入智能家居系统、实现跨设备联动的产品成为年轻消费群体的首选。 来源：沙利文分析   04 “反重力”前置过滤器：破解行业核心矛盾，净污分离重构过滤底层逻辑 作为本次报告重点拆解的创新品类，“反重力”前置过滤器正掀起净水赛道的底层技术革命，成为破解行业痛点的核心突破口。传统前置过滤器长期面临“高精度与大通量不可兼得”的行业顽疾：若提升过滤精度至25μm拦截更细小的虫卵、泥沙杂质，会大幅加快滤网堵塞速度，造成水流通量衰减、全屋水压下降；若要保障8T/h以上的大通量满足全屋多点用水，只能降低过滤精度，无法实现有效防护。同时，传统正向流道设计让杂质直接拦截在滤网表面，净水与脏污同腔，极易出现二次附着、冲洗不彻底、滋生细菌等问题，形成二次污染。 新一代“反重力”前置过滤器彻底重构了水路设计逻辑，其通过内部倒置水路设计，采用朝上的滤瓶装配端、朝下的排污端，实现净水“反重力”上溯、污水向下分流的净污分离效果，利用重力让杂质实时沉降到底部，全程实现净水与脏污物理隔离，大颗粒杂质提前沉降，仅细微杂质接触滤材，从根源上解决滤网堵塞、二次污染痛点。依托该结构创新，产品可实现25μm高精度过滤的同时，保持15T/h以上的大通量，兼顾过滤精度与用水体验，彻底打破了行业长期存在的技术矛盾。 市场竞争格局方面，新锐品牌凭借底层技术创新实现赛道突围，其中韦思卡尔作为“反重力”技术的先锋，凭借A-Gill活鳃叠片专利技术构建起核心壁垒，其WSP-85-80T系列产品入围AWE艾普兰奖，同时牵头参与净水行业团体标准起草，其成为该细分赛道的标杆企业；奥克斯等综合家电品牌也依托供应链优势加速布局，推动技术快速普及。 来源：沙利文分析   05 行业演进：迈入技术重构、场景深耕、价值升级的高质量发展新阶段 报告最终指出，当前中国智能净水家电行业的产品创新，已彻底告别同质化内卷与低价竞争，全面转向技术重构、场景深耕、价值升级的高质量发展新阶段。从“反重力”前置过滤器对行业核心痛点的底层破解、多合一前置过滤器对清洁效率与用户体验的全面升级，到稳压防护型产品对全屋水路的全链路安全守护、全屋智能联动款对智慧家庭生态的深度融合，核心品类的创新实践共同证明，真正的产品创新，始终以技术解决用户真实痛点为核心，用创新重构家庭用水健康体验。而随着技术持续迭代、消费需求持续升级、全屋智能生态持续完善，中国净水行业将迎来规模与质量的双重增长，持续释放巨大的市场潜力。

以真实调研丈量市场，用AI智能预见未来 5月24日，由高顿教育 ×  沙利文  × 阿里云联合主办，头豹研究院协办的「 2026第四届全国大学生预见未来行研大赛 」全国总决赛，于杭州阿里巴巴云谷园区圆满落幕。 从1743支战队集结，到579支队伍晋级复赛，再到全国10强巅峰会师，这场历时近2个月的大学生行业研究顶尖赛事，终于迎来了属于TA的高光时刻。 本届大赛延续“AI + 行业研究”的核心理念，聚焦真实商业命题与前沿产业趋势，并创新引入虚实结合市场调研、 Workflow 工作流与Skills技能体系搭建、AI质询问答等实践环节。赛事由高顿教育、沙利文、阿里云联合主办， 头豹研究院 协办，并获得特步、巨子生物、哈佛商业评论、FT中文网、 信睿科技评论 等品牌与媒体支持。来自全国高校的大学生学子，以专业研究回应时代议题，在真实市场与产业变化中探索未来方向，也让我们看见了当代大学生对商业世界的深度理解与前瞻思考。   01 决赛精彩回顾： 一场关于“未来行研”的青年表达 总决赛现场，来自高顿教育、沙利文、阿里云的主办方代表，以及来自高校、行业与媒体领域的多位嘉宾共同出席。 沙利文中国主管合伙人兼总裁王晨晖先生 ，以《黑箱、责任吸收器与波兰尼悖论：咨询业AI落地的三重障碍与信任重建》为主题发表分享，探讨了AI技术变革下的行业信任和人才核心竞争力问题。 *沙利文中国主管合伙人兼总裁王晨晖先生   同时，上海财经大学数字经济研究院副院长崔丽丽教授出席并致辞，以《在AI重构的时代，做价值的锚点》为题，为AI时代的大学生提出了三点切实可行的建议。 *上海财经大学数字经济研究院副院长崔丽丽教授   阿里云高校 AI 人才培养负责人李卓君女士 既肯定了参赛团队的创新洞察与实践潜力，也结合行业真实需求，为年轻研究者点明了商业分析与研究落地的进阶方向。 *阿里云高校 AI 人才培养负责人李卓君女士   随着比赛正式开启，全国10强战队在现场，围绕各自的研究课题展开最终路演，为大家展示了一次关于行业趋势、商业洞察与未来消费的精彩交锋。 选手们不仅完成了高质量的行业研究报告，更在有限时间内，通过 PPT与HTML可视化网页 现场呈现研究逻辑、核心观点与创新成果，并 现场接受评委和AI评委的尖锐提问 。来自企业、媒体、行业等领域的专业评委，共同参与评分，也让赛事更加贴近真实商业环境。 *总决赛十组选手路演风采   *总决赛十组选手路演风采   经过三个多小时的精彩比拼，最后， 巨子生物市场媒介总监南山、哈佛商业评论新媒体主编麻震敏对选手表现再次进行了深度复盘与总结点评。 *巨子生物市场媒介总监南山先生   *特步品牌策略总监庄娜娜女士   这场赛事不仅是能力的赛场，更是青年学子与行业前沿对话、链接真实商业世界的成长课堂。 *哈佛商业评论新媒体主编麻震敏女士   02 荣耀榜单揭晓， 恭喜所有获奖战队 以下为“2026预见未来行研大赛”决赛获奖结果，在此再次祝贺以下全部获奖队伍与参赛选手！   再次恭喜以上所有的菁英选手队伍！我们相信，大家的每一次熬夜打磨，每一次思维碰撞，都是一次自我突破。   03 为什么越来越多大学生 选择参加预见未来行研大赛？ 今天的年轻人，已经不满足于“知道行业”。 他们更希望：理解产业逻辑、洞察消费趋势、建立商业思维、提升数据分析能力，并真正站在真实市场环境中思考问题。 而AI预见未来行研大赛，正是在提供这样一个连接校园与产业的平台。 本届大赛最具意义的地方，或许不仅在于“研究结果”，更在于我们正在见证——AI时代下，行业研究方式与青年学习能力的重新定义。 从AI辅助行业信息搜集，到workflow工作流搭建、技能体系构建，再到AI质询问答与可视化表达，本届赛事让“AI+行研”不再停留于概念，而是真正成为大学生理解产业、分析市场、提升决策能力的重要工具。   END 2026 GOLDEN FINANCE 至此，2026第四届全国大学生预见未来行研大赛正式圆满收官。感谢所有合作伙伴、评委导师、院校老师与参赛选手的共同参与。也感谢每一位愿意投入时间、认真研究行业、持续探索未来的大学生。下一届预见未来行研大赛，期待与你再次相见。 但与此同时，我们也更加清晰地看到：AI可以提升效率，却无法替代真正的洞察；模型可以生成答案，但行业判断、商业逻辑与独立思考，始终来自人的理解与思辨。   更多精彩

2026年，中国医美注射类产品市场正处于结构性转型的关键阶段。 从整体格局来看，行业正从单一材料的规模扩张，转向多材料协同、技术创新与合规能力并重的发展新周期。各类注射产品在材料科学、生物工程及临床应用层面持续取得进展，共同拓展着面部年轻化与组织修复的临床边界。 与此同时，监管体系的系统性完善正在重塑行业运行规则。税收规范、药械追溯及专项治理等举措的深入推进，推动合规门槛全面提升，也为行业长期健康发展奠定制度基础。技术层面，人工智能在诊疗决策中的辅助价值日益显现，合成生物学对原料供给方式的革新潜力亦在逐步兑现。消费端，不同层级市场与差异化需求并行增长，为产业提供了多元化的价值空间。 基于在生命科学与前沿医学领域的长期追踪与深度研究，弗若斯特沙利文（Frost & Sullivan，以下简称“沙利文”）拟于2026年正式发布《2026医美注射类产品蓝皮书》，并诚邀行业内的优秀企业与产业伙伴共同参与，携手推动中国医美注射类产品产业的规范化与创新发展。 研究内容 蓝皮书将系统梳理2026年中国医美注射类产品行业的发展格局与演变趋势，围绕玻尿酸、胶原蛋白、肉毒毒素、再生材料、 外泌体 及新兴材料等核心品类，从材料科学进展、临床应用拓展、监管政策演进、产业竞争格局及消费需求变迁等维度展开研究，构建对行业整体态势的结构性认知，旨在为行业参与者提供专业参考。 一、材料科学进展 蓝皮书将深度解析各类注射材料在2026年的关键技术突破： 玻尿酸 领域， 交联工艺 的精细化迭代与低修饰度技术路线持续升级产品性能； 胶原蛋白 领域，重组表达体系在表达量、生物活性与批次一致性方面取得实质性进展，动物源提取工艺则在免疫原性控制与活性保留的平衡上持续优化； 肉毒毒素 领域，重组制备路径与新型血清型的差异化开发拓展了临床选择空间； 再生材料 领域，原料规模化生产正在改变供给结构； 新兴材料 方面，合成生物路径下多种新型生物聚合物的产业化可行性获得验证。 二、核心应用场景 蓝皮书将通过对医美机构与终端消费者的深度访谈，结合临床文献与行业数据，系统考察注射类产品在面部容积填充与轮廓塑形、动态皱纹管理、组织再生与肤质改善、复合式治疗方案等核心场景中的应用现状，并重点关注适应症体系向精细部位延伸的趋势。 机构端访谈将围绕产品选择决策逻辑、治疗方案设计思路、联合治疗策略、并发症管理经验及合规采购考量等维度展开； 消费者端访谈将覆盖信息获取路径、产品认知水平、决策影响因素、疗效预期与实际满意度、复购与推荐意愿、价格敏感度及对新兴材料接受度等关键议题，力求从供需双向呈现注射类产品在真实临床场景与消费决策中的价值定位与优化空间。 三、行业发展驱动因素 蓝皮书将重点分析行业的多重驱动力：消费群体年龄结构与审美观念的演变催生差异化需求，下沉市场渗透率提升带来增量空间，合成生物学与AI技术的交叉赋能重塑研发效率与供给方式，监管框架的系统性完善推动行业进入规范化发展轨道，资本对创新材料与平台的持续关注为产业整合提供动力。 四、行业竞争格局 蓝皮书将全面呈现中国医美注射类产品市场的竞争生态，以产品类型为研究主线，对 玻尿酸、胶原蛋白、肉毒毒素、再生材料、新兴材料等 领域的技术路线、产品管线布局、临床注册进展及商业化策略，并借由具体案例揭示该赛道的竞争逻辑与发展趋势。旨在为读者提供兼具行业广度与深度的结构性洞察。 五、监管与准入政策 蓝皮书将系统梳理中国医美注射类产品的监管框架更新，包括2026年新发布的相关注册审查指导原则、药械追溯体系建设要求、重点品类的专项治理措施，以及主要国际市场的监管动态对比，为产品的合规化开发与市场准入提供参考依据。 六、代表性企业展示 蓝皮书将分析全球及中国医美注射领域的资本市场表现，包括企业融资、产品授权交易及产业整合事件。此外，蓝皮书将设立企业专题章节，对国内外代表性企业进行深度介绍，涵盖技术路线、产品管线、商业化进展及战略布局，在产业全景图中呈现差异化定位与核心竞争力。 沙利文诚邀医美注射类产品领域优秀企业共同参与本次蓝皮书，联合产业链内多方共同参与研究与发布过程，在专业分析框架下形成对行业发展的理性表达与共识积累，携手推动中国医美注射类产品产业的规范化与可持续发展。 发布亮点 1. 蓝皮书全球发布，以技术实力提升行业声量 作为医美注射类产品领域的系统性研究成果，本次蓝皮书将通过沙利文官网、全球媒体矩阵及生命科学垂直渠道进行广泛发布。报告将深度呈现参与企业的核心优势，重点展示技术平台创新性、产品管线布局深度、关键数据及监管里程碑进展、规模化生产能力等。通过差异化呈现，帮助市场建立对企业技术实力与产业化能力的清晰认知，提升行业影响力与品牌公信力，为企业提供权威发声与集中展示的窗口。 英文版亦将同步登陆全球知名通讯社（美联社等）、主流财经媒体（雅虎财经等）、北美财经媒体和网站（商业内参、道琼斯市场观察、Benzinga、华尔街内参等）以及全球各区域媒体渠道，进一步扩大企业在国际市场的品牌声量，助力中国医美注射类产品企业推进全球化品牌建设与技术合作。 2. 链接产业生态，拓展合作网络 蓝皮书将搭建连接医美注射类产品产业链多方主体的交流平台，推动不同定位企业之间的深度互动与资源对接。原料企业、产品企业、医美机构等均可对自身业务进行差异化呈现，通过精准匹配，促进能力的互补结合，增进与投资机构及产业伙伴的相互认知，为技术协同、资源整合及商业拓展创造更多可能。 3. 夯实专业定位，塑造品牌辨识度 依托蓝皮书对医美注射类产品技术、商业转化路径及监管科学的系统研判，参与企业的专业积累将得到客观呈现。通过研究内容的深度呈现，提升企业在技术平台、产品进展或生产能力方面的辨识度与影响力，夯实差异化市场定位。 4. 对接多元资本，把握战略机遇 依托沙利文在生命科学领域的投资机构与产业伙伴网络，蓝皮书的发布将有效提升医美注射类企业的行业能见度，精准对接多元资本类型：处于早期研发阶段的企业，可凭借其技术平台的创新性吸引关注底层材料突破的创投基金；进入临床或注册申报阶段的企业，可对接聚焦产品管线价值与获批预期的医疗专业资本及大型企业BD部门；已获证并启动商业化的企业，则可凭借产品矩阵与市场份额吸引战略投资者与产业并购方的关注。蓝皮书致力于在企业与多元资本之间搭建高效沟通桥梁，助力其在融资、技术授权、并购及战略合作中占据主动。 5. 深化长期合作，共创产业价值 通过蓝皮书合作建立的深度交流基础，沙利文可与参与企业探索多元协同方向，包括品牌传播、投融资咨询、增长战略等方向。双方有望在本次合作基础上建立长期伙伴关系，共同应对行业变革，携手推动医美注射类产品产业的高质量发展。 参与合作 请联系我们 沙利文医疗健康事业部 知识中心 邮箱：HCknowledgecenter@frostchina.com   沙利文中国医疗健康事业部 咨询总监 汪鹏 邮箱：aaron.wang@frostchina.com   沙利文中国医疗健康事业部 项目经理 吕晓彤 邮箱：xiaotong.lv@frostchina.com 长按扫描下方二维码 我们将与您取得联系

近年来，在技术迭代推力与再生医学临床需求牵引的双重作用下，细胞外基质（ Extracellular  Matrix, ECM）正加速从基础研究迈向临床转化与工业化量产。   在技术端，脱细胞工艺的持续突破，显著缓解了天然生物材料 “抗原去除与结构保留”的核心矛盾；合成生物学技术则以重组表达路径从源头规避免疫原性，并结合工程化交联改性，使材料体内降解与组织再生速率趋于协同可控，为规模化制备与全生命周期质控奠定了坚实的技术基石。   在应用端，以 ECM为核心支架的仿生体外三维微环境，正与生物反应系统深度融合，持续拓展其在临床医学、医疗美容、前沿生命科学中的应用疆界。   当前，伴随全球及中国监管准入路径的日渐清晰、复杂难愈性创面修复需求的激增，以及再生医学美学消费的爆发，中国 ECM产业正处于从“实验室制备”向“标准化、规模化、商品化及合规化应用”转型的关键窗口期。如何在技术路线迭代与监管科学日趋完善的进程中把握发展机遇，正成为链条内研发企业、科研机构及资本方共同聚焦的重大战略议题。   基于在生命科学与前沿医学领域的长期追踪与深度研究，弗若斯特沙利文（ Frost  & Sullivan，以下简称“沙利文”）拟于2026年正式发布《2026全球ECM行业白皮书》，并诚邀行业内的优秀企业、科研机构与产业伙伴共同参与，携手推动中国ECM产业的规范化与创新发展。 研究内容   本次白皮书将系统梳理 ECM行业的发展现状与未来趋势，围绕ECM技术迭代、核心应用场景、发展驱动因素、行业竞争格局及监管与准入政策等展开研究，构建对行业整体格局的结构性认知，旨在为行业参与者提供专业参考。   一、 ECM技术路径   报告将深度解析传统脱细胞工艺（ dECM）在“抗原去除与结构保留”之间的平衡与突破，并结合合成生物学进展，探讨重组ECM蛋白的质控一致性，从而理清ECM材料向高纯度、低风险方向演进的产业路径。   二、 ECM核心应用场景   研究将跨越外科创伤修复与组织工程补片，延伸至再生医美注射，以及体外仿生肿瘤微环境和类器官高通量药物筛选等前沿领域。   · 外科创伤修复 ： ECM材料促进组织再生、减少瘢痕产生；   · 组织工程补片 ： ECM材料用于修复或替换受损组织，提供力学支撑和细胞生长支架；   · 医美注射类产品 ： ECM材料通过激活成纤维细胞实现自身胶原新生；   · 体外仿生肿瘤微环境构建 ：模拟体内 ECM环境，用于研究肿瘤侵袭、转移和药物响应；   · 类器官高通量药物筛选 ：利用 ECM水凝胶等培养类器官，提高药物筛选的准确性和效率。   三、 ECM行业发展驱动因素   白皮书将重点剖析 ECM行业的多重宏观驱动力：人口老龄化催生慢性难愈性创面刚需，消费升级带动再生医美与高端修复增量市场，底层生物工程装备成熟奠定规模化量产红利，监管科学路径日趋明朗释放合规催化效应，合成生物学与工程化交联技术突破赋予品类拓展动能，全球资本持续涌入加速产业化整合浪潮等。   四、 ECM行业全球竞争格局   报告将分析欧美企业的多中心临床数据积淀，与中国本土企业在重组蛋白赛道依托合成生物学构建的差异化产业优势，全景式呈现全球多元生态下的竞合现状。   五、 ECM监管与准入政策   白皮书将系统梳理中国、美国、欧盟等全球主要国家和地区的 ECM植入级产品监管与准入政策，为前沿材料的合规化应用与跨国BD授权提供权威的科学参考。   六、 ECM行业资本表现与代表性企业展示   报告将分析全球及中国 ECM领域的资本市场表现，包括研发企业融资情况、授权交易及兼并购事件。最后，白皮书将设立企业专题章节，对国内外ECM研发企业进行深度介绍，涵盖公司发展历程、业务布局、技术优势及最新研发进度，在产业全景图中呈现企业的差异化定位与核心竞争力。   沙利文诚邀ECM领域优秀企业共同参与本次白皮书，联合产业链内多方共同参与研究与发布过程，在专业分析框架下形成对行业发展的理性表达与共识积累，携手推动中国ECM产业的规范化与可持续发展。 发布亮点   1. 白皮书全球发布，以技术实力提升行业声量   作为 ECM领域的系统性研究成果，本次白皮书将通过沙利文官网、全球媒体矩阵及生命科学垂直渠道进行广泛发布。报告将深度呈现参与企业的核心优势，重点展示技术平台创新性、产品管线布局深度、关键数据及监管里程碑进展、规模化生产能力等。通过差异化呈现，帮助市场建立对企业技术实力与产业化能力的清晰认知，提升行业影响力与品牌公信力，为企业提供权威发声与集中展示的窗口。   英文版亦将同步登陆全球知名通讯社（美联社等）、主流财经媒体（雅虎财经等）、北美财经媒体和网站（商业内参、道琼斯市场观察、 Benzinga、华尔街内参等）以及全球各区域媒体渠道，进一步扩大企业在国际市场的品牌声量，助力中国ECM企业推进全球化品牌建设与技术合作。   2. 链接产业生态，拓展合作网络   白皮书将搭建连接 ECM产业链多方主体的交流平台，推动不同定位企业之间的深度互动与资源对接。研发企业、生产企业等均可对自身业务进行差异化呈现，通过精准匹配，促进研发与生产能力的互补结合，增进与投资机构及产业伙伴的相互认知，为技术协同、资源整合及商业拓展创造更多可能。   3. 夯实专业定位，塑造品牌辨识度   依托白皮书对 ECM技术、商业转化路径及监管科学的系统研判，参与企业的专业积累将得到客观呈现。通过研究内容的深度呈现，提升企业在技术平台、产品进展或生产能力方面的辨识度与影响力，夯实差异化市场定位。   4. 对接多元资本，把握战略机遇   借助沙利文在生命科学领域的投资机构与产业伙伴网络，白皮书发布将有效提升企业能见度，对接多元资本类型。早期研发企业可触达关注技术平台创新性的 VC/PE；临床阶段企业可对接关注后期临床资产与商业化潜力的产业资本及Big  Pharma BD；规模化生产企业则可吸引关注制造能力的战略投资者。为企业与多元资本之间搭建沟通桥梁，在融资、技术授权、并购及战略合作中占据主动位置。   5. 深化长期合作，共创产业价值   通过白皮书合作建立的深度交流基础，沙利文可与参与企业探索多元协同方向，包括品牌传播、投融资咨询、增长战略等方向。双方有望在本次合作基础上建立长期伙伴关系，共同应对行业变革，携手推动ECM产业的高质量发展。 参与合作 请联系我们 沙利文医疗健康事业部   知识中心   邮箱： HCknowledgecenter@frostchina.com   沙利文中国医疗健康事业部   咨询总监   汪鹏   邮箱： aaron.wang@frostchina.com   沙利文中国医疗健康事业部   项目经理   吕晓彤   邮箱： xiaotong.lv@frostchina.com   长按扫描下方二维码 我们将与您取得联系

  为全面贯彻落实党的二十届四中全会和习近平总书记关于食品药品产业新质生产力和高质量发展的一系列重要指示精神，在海南自贸港全岛正式封关运作和我会成功举办 “ 2025 中国食品药品医疗器械化妆品新质生产力和高质量发展大会”的大背景下，中国食药安全促进会服务国家发展战略，见证封关取得的优异成绩，汇聚新质生产力资源与智慧，持续助力海南自贸港现代化建设， 2026 中国食品药品医疗器械化妆品新质生产力和高质量发展大会于 2026 年 5 月 8 日至 11 日在海南省三亚市顺利举办，并于 10 日召开“ mRNA 技术的应用边界在哪里？”平行论坛。本次平行论坛研讨重点包括应用边界突破基石—— mRNA 底层技术、边界突破引擎—— AI 创新、 818 号令如何影响 mRNA 行业发展等，邀请药品医疗器械等领域国内外知名院士、专家学者和企业精英等，共话世界前沿科学成果，共建政产学研金服用融合发展平台，共谋政策发展红利，共享全球科技资源，有效推动“三品一械”领域新质生产力高质量发展和高水平安全。       弗若斯特沙利文（ Frost  & Sullivan, 以下简称 “沙利文”）中国医疗健康事业部咨询总监陈萧芮应邀出席，并发表演讲。 沙利文中国医疗健康事业部咨询总监陈萧芮 818 号令与 828 号令协同构建了生物医学创新从临床探索到商业化转化的双轨监管体系。 818 号令与 828 号令分别对应生物医学新技术的“临床研究备案—转化应用”路径及药品注册审批路径：前者聚焦新技术在合规医疗机构内的临床验证与转化应用，后者侧重标准化药品的注册上市及全国范围内流通。两类路径在监管主体、收费机制、审批周期等方面存在显著差异，共同构建覆盖生物医学创新从早期探索到规模化商业化的双轨监管框架。 陈萧芮介绍到， 818号令在强化监管约束的同时，建立了“临床研究备案”到“转化应用”的规范化路径，为mRNA疗法等前沿技术在合规框架内开展临床验证与转化应用提供制度基础；该路径与既有药品注册审批路径并行，为不同成熟度和标准化程度的技术提供差异化落地选择。818号令明确临床转化应用的评估及审批时限，为前沿技术提供更高效的临床转化路径。   818号令的实施将通过规范与促进生物医学新技术的临床研究和应用，为整个生物医药产业积累宝贵的前期数据资源。这些在真实世界研究中产生的安全性与有效性数据，在技术成熟后，可为后续申报药品提供重要参考，从而降低重复试验成本，提高整体研发效率与成功率。同时，新技术的发展也会倒逼和拉动上游产业链创新，提升整个技术体系的标准化与可复制性。技术与产品路径并非割裂，而是可以形成“技术孵化产品、产品优化技术”的良性循环。mRNA技术具备开发周期短及平台化属性强等特点，可在较短时间内完成从序列设计、体外验证到GMP临床级样品制备的全过程。在818号令建立的“临床研究备案—转化应用”路径下，三甲医疗机构可在合规框架内开展早期临床探索，并联合具备GMP能力的技术服务方完成制备与质量控制，从而在满足伦理审查及监管要求的前提下，加速候选产品的临床验证进程。相较传统完全依赖药品注册路径的开发模式，该机制为mRNA等前沿技术提供了更具可操作性的临床转化通道，有助于缩短从科研设想到临床验证的周期。   陈萧芮进一步指出， 818号令的出台将加速mRNA行业分化：缺乏合规临床路径及真实数据支撑的项目将面临更高淘汰压力，而具备平台化能力、完整开发体系及规范临床转化能力的企业将进一步巩固竞争优势。与此同时，资本评价逻辑将由单纯关注技术潜力，转向更加重视临床可行性、合规能力及商业转化能力。   陈萧芮总结表示， 818号令在为mRNA等前沿技术提供规范化落地通道的同时，也通过责任主体明确、研究期零收费、备案方案约束及全过程可追溯等要求，系统性提升临床研究的伦理合规、安全管控和数据可信度。政策短期内将对研发节奏、商业化路径及中小企业运营形成一定压力，但中长期有助于推动行业出清、资源向具备平台化与体系化能力的企业集中，并促进mRNA行业向高质量、可持续及国际化方向发展。

当前我国医疗器械产业正处于从跟跑向并跑、领跑转型的关键阶段，为助力我国医疗器械行业高质量发展，加速行业创新与资源整合， 5 月 8-9 日，“ 2026MDI-China 医疗器械创新·合作大会”（第三届 MDI 大会）在无锡成功举办。弗若斯特沙利文（ Frost  & Sullivan, 以下简称 “沙利文”）中国医疗健康事业部咨询总监汪鹏应邀出席，并发表演讲。   沙利文中国医疗健康事业部咨询总监汪鹏 汪鹏指出，随着经济发展、生活水平提高、信息传播加速以及观念转变等因素影响，对 “颜值”的追求已深入到每个消费者的意识中，“颜值经济”随之兴起。医疗美容近年来受到普遍关注，以整形、抽脂等手术类医美项目，以及以注射类和声光电类为主的非手术类医美项目渗透率不断普及，接受度和认可度不断提高。非手术类医美项目的安全性和有效性显著提升，又因其微创、快捷等优势受到消费者的青睐。   在监管环境方面，汪鹏强调，合规已成医美行业发展的共识，是挑战也是机遇。自 2002年卫生部发布《医疗美容服务管理办法》以来，中国医美行业经历了监管框架设立时期和合规化、规范化时期。近年来，卫健委等多部门持续开展严厉打击非法医疗美容专项行动，规范医疗美容服务，加强行业监管。2023年，市场监管总局等十一部门发布《关于进一步加强医疗美容行业监管工作的指导意见》，对医美行业准入管理、事中事后综合监管等做出较全面规定。监管政策的完善加速了行业洗牌，减少了不正当竞争，消费者信任不断加强，行业环境持续向好。但同时，技术设备升级与注册申报标准严格，企业合规成本增加，定价压力加大，行业资源优化，市场集中度提升，产品安全性提高，消费者认可度提升。   汪鹏介绍到，全球非手术类医美市场规模从 2017年的210亿美元增长至2021年的321亿美元，预计2025年将达723亿美元、2030年突破1,594亿美元，增速在2021-2025年间高达22.5%，此后仍保持17.1%的年复合增长。中国非手术类医美市场同样快速扩容，从2017年的595亿元增至2021年的1,573亿元，预计2030年可达4,014亿元；其中注射类项目的地位尤为突出，其市场规模从2017年的194亿元增长至2021年的505亿元，预计2025年将达980亿元，首次与非注射类基本持平（占比50.1%），到2030年进一步增至1,968亿元，占非手术类市场近半壁江山。整体来看，注射类医美项目在中国市场正从补充角色转变为核心增长引擎，增速虽随基数扩大有所放缓（2025-2030年CAGR为15.5%），但绝对增量依然可观，驱动中国乃至全球非手术类医美市场持续扩张。   汪鹏进一步分析了医美注射类产品的市场格局。目前医美注射类产品以玻尿酸类、胶原蛋白类、再生材料类和肉毒素类为主，多因素推动领域快速发展。医美消费接受度提高，消费水平提升；政策完善促进行业良性发展；技术进步促进产品升级；数字化营销渠道助力，消费者教育加强。医美注射类产品的高景气发展激活产业链上下游各个环节不断完善，多数企业向上下游延伸业务覆盖以巩固行业地位，下游的需求反馈与上游的原材料创新联动，带动中游产品营收增长。   针对玻尿酸这一主导品类，汪鹏介绍，玻尿酸由双糖单位链接形成，在人体内广泛分布，因其粘弹性和强大的保水性能在润滑关节、调节血管壁通透性、促进创伤愈合等过程中起到重要作用，在医疗、化妆品、功能性食品等领域中有着广泛应用。分子量是玻尿酸的一个重要参数，按分子量大小可分为高分子量玻尿酸（分子量 ≥1×10⁶   Da）、低分子量玻尿酸（分子量在1×10⁴–1×10⁶   Da之间）和寡聚玻尿酸（分子量≤1×10⁴   Da）。交联程度的不同也会带来性能差异：高交联度产品机械强度更高、塑形能力更强，适合鼻部、下巴等坚硬部位塑造；中交联度产品适用于皱纹、凹陷填充；低交联度产品更柔软，适合唇部等动态填充；低分子量、低交联/非交联玻尿酸常作为“水光针”注射至真皮层，利用其保湿、补水作用改善皮肤状态。   在产业竞争格局上，汪鹏指出，随着工艺水平不断提高，本土玻尿酸生产企业在全球极具竞争力。玻尿酸的工业化生产主要依赖动物组织提取技术和微生物发酵技术两大途径。相较于动物组织提取方式，微生物发酵法不受动物资源限制，能够在大规模发酵过程中直接生成游离态的玻尿酸，从而简化并提高纯化效率，降低生产成本，更适应大规模工业化生产需求；此外，由于避免了动物源性材料，消除了可能的致病病毒污染风险。交联技术作为玻尿酸企业的核心技术之一，各企业纷纷布局自有交联技术专利，以实现对交联度、机械强度、粘弹性等更精准的调控。   关于再生制剂类材料，汪鹏表示，再生制剂类材料通过刺激人体胶原蛋白再生起到美容作用，以维持时间长、效果自然、生物可降解等优势受到关注。在肉毒素领域，中国已有 7款医美注射类肉毒素产品获批上市，国内多家企业加速布局，多款产品处于上市申请或Ⅲ期临床阶段。   在创新趋势方面，汪鹏表示，新材料的突破、新技术的发展以及新理念的提出，正在为市场和消费者提供更多“变美”新思路。精准医疗推动定制化“变美”方案，结合基因检测与AI分析，根据个人皮肤类型、遗传倾向、过敏史等数据，为每位客户提供量身定制的治疗计划；通过AI算法分析面部比例、3D扫描，结合VR/AR技术，预先展示美容效果，帮助医生与客户更直观地沟通预期效果。新材料与新产品的不断涌现正引领着医美行业的潮流新风尚，如外泌体、干细胞等抗衰医美新产品的研发，超声炮、黄金微针、热玛吉等声光电类治疗设备适应症的拓展，将进一步推动爱美人士的市场热情并引领新的医美风尚。同时，医美与健康管理相结合，实现科学“变美”，包含体检、精力管理、身体理疗、心理咨询等的一站式健康美容管理中心开始出现，帮助消费者更好地实现科学变美。

在健康中国 2030 战略深入推进、十五五规划重点布局大健康产业的时代背景下，中国保健食品行业正迎来结构性增长与高质量发展双重机遇。市场由传统“营养补充”加速向功能化、精准化、场景化、长期化演进，覆盖膳食补充、慢病管理、运动营养、体重管理、肠道健康、睡眠健康、银发健康等核心场景；监管体系持续完善、原料创新与循证医学深化、产业资本密集布局，推动行业从高速增长迈向高质量发展新阶段。 在此关键节点，弗若斯特沙利文（ Frost  & Sullivan ）联合头豹研究院，正式启动《中国保健食品行业发展白皮书（ 2026 ）》编写工作，现诚邀行业优质企业深度合作，共研产业趋势、共树品牌标杆、共拓全球市场。 报告研究内容   本白皮书以行业专业视角、丰富数据支撑、优质案例实践，构建行业系统性认知框架，为企业、资本、监管及产业链各方提供前瞻决策参考。   核心研究内容   1. 行业全景解析：界定行业边界与监管体系，梳理发展历程与市场演变，拆解从 “单一补充”到功能化、精准化、场景化的转型逻辑，分析产业链生态、投融资趋势与核心驱动因素。   2.重点赛道深耕：聚焦肠道健康、免疫调节、体重管理、运动营养、银发健康、女性健康等高增长细分领域，揭示消费需求、技术创新与市场潜力。   3.全链路赋能路径：覆盖研发创新、功效评价、商业化运营、技术跨界融合四大环节，解析原料开发、合成生物学、AI配方优化、全链路溯源等核心竞争力构建方法。   4.标杆企业案例：收录优质企业实践，全景呈现产品布局、技术平台、供应链优势、合规能力、全球化进展，打造行业可复制的发展范本。   5.未来趋势研判：前瞻行业技术方向、政策走向、消费变革与全球化机遇，指引企业战略布局。   企业核心权益   1.行业内容共创权益：深度参与白皮书研究方向、核心议题、趋势判断研讨，为行业分析、赛道解读提供专业建议，凸显企业行业领导力。   2.企业案例定制展示权益：在白皮书核心章节、企业案例专篇定制植入内容，全面呈现企业发展历程、核心产品、技术创新、供应链壁垒、全球化布局等优势，突出差异化竞争力，实现权威背书。   3.全球全媒体传播权益：白皮书将在沙利文中文媒体矩阵及垂直媒体同步发布；英文版本将收录于沙利文全球官网，并通过全球主流财经及行业媒体进行多语种传播。   4.行业发布会参与权益：受邀参与白皮书线上/线下发布会，企业代表可出席发布仪式、参与圆桌论坛、进行主题分享，直面行业专家、投资机构与产业链伙伴，强化专业影响力。   5.资本市场精准触达权益：依托沙利文&头豹全域资源，定向对接消费基金、产业资本、券商研究所、头部渠道平台，助力企业提升资本市场关注度，拓展投融资、产业链合作机会。 我们的优势：权威背书 +丰富经验+全域资源   1.权威机构背书   沙利文成立于 1961年，拥有65年全球咨询经验，深耕中国市场28年，是全球领先的投资与企业增长咨询机构；头豹研究院为国内知名产业研究平台，双强联合保障报告专业性与公信力。   2.大健康领域深耕积淀   连续数年发布《中国医疗大健康产业发展白皮书》， 2025年已发布《肠道菌群行业发展现状与未来趋势白皮书》与《2025年中国益生菌市场白皮书》等多项重磅报告，具备成熟研究体系与实践经验。   3.全域资源赋能   整合海内外媒体矩阵、 300+投资机构、1,000+产业链伙伴、科研院校资源，提供“品牌传播+资本对接+产业合作”一站式盈利支持。     白皮书发布计划   项目启动时间      ： 2026年5月   报告完整版发布      ： 2026年8月4-5日第二十届沙利文全球增长、科创与领导力峰会暨第五届新投资大会     参与合作     请联系我们     诚邀保健食品行业原料、研发、生产、品牌、渠道等各环节领军企业，携手打造2026年行业权威标杆白皮书，共启高质量发展新征程！ 沙利文中国   高级合伙人兼董事总经理   杨晓骋   邮箱： jacky.yang@frostchina.com   沙利文中国   咨询经理   荆婧   邮箱：jing.jing@frostchina.com  长按扫描下方二维码，我们将与您取得联系

当技术爆炸与动荡交织，什么才是值得信任的引领？一家65年的顶级咨询机构，如何定义这个时代的"领创精神"？ When technological explosion and turbulence intertwine, what kind of leadership is truly worthy of trust? How does a premier consulting institution with 65 years of history define the "spirit of pioneer innovators" of this era? 世界从未如此复杂，也从未如此丰盛。 The world has never been so complex, nor so abundant. AI、新能源、生物科技等领域竞相迸发，技术创新如烟花般绚烂绽放，每一个方向都在许诺一个崭新的未来。然而另一边，技术的加速度与国际局势的波动交织在一起，人们在信息洪流中反而更难辨清方向：机会越多，越怕选错；声音越杂，越渴望指引。 In fields such as AI, new energy, and biotechnology, innovations are erupting in fierce competition, with technological breakthroughs blooming as brilliantly as fireworks—each direction promising a brand-new future. Yet on the other side, the acceleration of technology and the fluctuations of the international landscape are intertwined, leaving people even more unable to discern their bearings amid the torrent of information: the more opportunities there are, the greater the fear of choosing wrongly; the more voices there are, the stronger the longing for guidance. 哪些发展方向值得关注？哪些企业值得信任？ Which directions of development deserve attention? Which enterprises are worthy of trust? 今年恰逢弗若斯特沙利文（Frost & Sullivan，简称"沙利文"）成立65周年，他们将年度主题词定为"信任"。这家陪伴了上万家企业上市、转型与变革的增长咨询公司，始终在做一件事——通过深度研究，尽可能消除信息不对称，为资本市场提供最可信的判断。 This year marks the 65th anniversary of Frost & Sullivan, which has chosen "Trust" as its annual theme. This growth consulting firm, having accompanied tens of thousands of enterprises through IPOs, transformations, and changes, has always been doing one thing—eliminating information asymmetry to the greatest extent possible through in-depth research, and providing the capital market with the most credible judgments. 自2025年开始，福布斯中国与沙利文连续合作举办行业发展领创者评选，试图进一步回答，在喧嚣与迷雾之中，究竟什么才是值得托付的引领？ Since 2025, Forbes China and Frost & Sullivan have collaborated consecutively to host the Awards of Pioneer Innovators in Industry Development, seeking to further answer this question: amid the noise and fog, what kind of leadership is truly worthy of entrustment? 日前，2026福布斯中国行业发展创作者评选颁奖盛典圆满落幕。在颁奖环节正式开始前，我们与弗若斯特沙利文全球高级副总裁、亚太区联合主席、中国董事长王昕博士进行了一场对话，探讨“领创”二字的份量，以及信任何以成为这个时代最稀缺的资产。 Recently, 2026 Forbes China Pioneer Innovators in Industry Development Selection Gala Banquet concluded successfully. Before the official award presentation began, we had a conversation with Dr. Neil Wang, Global Senior VP, Co-Chairman of Asia Pacific, and Chairman of China, Frost & Sullivan, to explore the weight of the word "pioneering" and why trust has become the most scarce asset of this era. 01 小荷才露尖尖角 The Lotus Bud Just Showing Its Tip 3月18日上午，上海宝格丽酒店宴会厅外。红毯已经铺好，身着西装的安保人员在入口处来回巡视，数十位工作人员手里攥着流程单，步履匆匆，空气中弥漫着一种紧张却充满期待的气氛。 On the morning of March 18, outside the ballroom of the Bvlgari Hotel Shanghai. The red carpet had already been laid out; security personnel in suits patrolled back and forth at the entrance; dozens of staff members clutched their run-of-show sheets, hurrying to and fro. The air was filled with an atmosphere that was tense yet brimming with anticipation. 紧张，是因为这场备受瞩目的盛会不容有失。而期待，是因为今晚，一批在各自领域内成绩斐然的名字将登上属于他们的舞台。沙利文要将最能引领中国未来发展的领创者们郑重地介绍给世界。 The tension stemmed from the fact that this highly anticipated grand event brooked no mishap. The anticipation arose because tonight, a group of names that had achieved remarkable success in their respective fields would ascend to a stage that belonged to them. Frost & Sullivan would solemnly introduce to the world the pioneer innovators best positioned to lead China's future development. 王昕拆解"领创"两个字："'领'就是领先。第一个吃螃蟹需要冒险，敢为天下先，但同时也意味着有巨大的机会。我们觉得任何一个行业必须有领军人物和领军企业，它们对细分赛道、甚至对更大的行业资源有先锋示范作用。'创'就是创新，最好是开天辟地式地创造出一些新的东西。可以是一个引领时代的新业务模式，一种新的潮流，或者一个新的想法。最重要的是要对过去的墨守成规说'不'，要打破那些条条框框的束缚。" Dr. Neil Wang deconstructed the two characters "ling chuang": "'Ling' means leading. Being the first to eat the crab requires taking risks and daring to be the trailblazer, but it also signifies enormous opportunity. We believe that every industry must have leading figures and leading enterprises, which serve as pioneering exemplars for niche tracks and even for broader industry resources. 'Chuang' means innovation, preferably the creation of something new in a groundbreaking manner. It can be a new business model that leads the era, a new trend, or a new idea. Most importantly, it means saying 'no' to the rigid adherence to conventions of the past, and breaking free from the shackles of those rules and constraints." 今年入选的领创者们，正是这样一群企业与个人。他们中的多数是深耕细分赛道的创新型成长期企业，亦不乏手握核心技术的初创新势力。虽然尚未长成行业巨头，但是他们凭借前瞻的视野与破界的创新力，已成为各自领域的先行者。 This year's selected pioneer innovators are precisely such a group of enterprises and individuals. The majority are innovative growth-stage enterprises deeply rooted in niche tracks, while there is also no shortage of nascent new forces armed with core technologies. Though they have not yet grown into industry giants, they have become trailblazers in their respective fields by virtue of their forward-looking vision and boundary-breaking innovative capabilities. 九层之台，起于累土。不管是巨无霸的跨国公司还是百年企业，都是一点一滴积累而成，涓涓细流才能汇成汪洋大海。因此王昕坚信，这些成长期企业和初创企业是产业发展的根基，更是未来商业格局的孕育者。 A nine-story tower begins with a pile of earth. Whether it is a behemoth multinational corporation or a century-old enterprise, all are built up drop by drop; only trickling streams can converge into a vast ocean. Therefore, Dr. Neil Wang firmly believes that these growth-stage and start-up enterprises are the foundation of industrial development, and even more so, the incubators of future commercial landscapes. 根基的成长，往往伴随着脆弱。根据沙利文多年来在全球范围内的大量研究结果显示，初创企业有将近97%甚至更高，在创业的前两三年面临极高的失败风险。"就好像一个新生的幼鸟，经不住狂风暴雨。在前两年里，它极度需要关注，需要背书，需要帮助，需要唤起合作伙伴、客户对它的认可。" The growth of foundations is often accompanied by fragility. According to extensive research results accumulated by Frost & Sullivan over many years across the globe, nearly 97% or even more of start-up enterprises face extremely high risks of failure during the first two or three years of their founding. "It is like a newborn fledgling, unable to withstand violent storms. In the first two years, it desperately needs attention, endorsement, assistance, and the need to evoke recognition from partners and customers." 他引用了一句诗："小荷才露尖尖角，便有蜻蜓立上头。"沙利文愿做"蜻蜓"，为"小荷"采蜜传粉。 He quoted a line of poetry: "The lotus bud just shows its tip, and already a dragonfly perches atop." Frost & Sullivan is willing to be the "dragonfly," gathering nectar and pollinating for the "lotus bud." 与2025年相比，本届入选者的画像更为鲜明。多位评委不约而同地发现，海归、年轻、高学历是这一届的突出特点，"跟我们几十年前改革开放之初，很多创业者从基层一点点做起来不一样。这些人有全球化视野，在最前沿的高科技解读方面特别牛。"王昕说。 Compared with 2025, the profile of this year's selected pioneer innovators is more distinct. Multiple judges independently discovered that returnees from overseas, youth, and high educational attainment are the prominent characteristics of this cohort. "This is different from the early days of reform and opening-up several decades ago, when many entrepreneurs worked their way up from the grassroots level bit by bit. These people have a globalized vision and are particularly formidable in interpreting the most cutting-edge high technology," Dr. Neil Wang said. 但技术领先不等于一切。王昕补充了一个关键观察："好的科技不代表有好的市场，也不代表有好的推广前景。顶级的技术，不一定能带来巨大的市场效益和投资效益。" But technological leadership does not equal everything. Dr. Neil Wang added a crucial observation: "Good technology does not necessarily mean a good market, nor does it mean promising prospects for promotion. Top-tier technology does not automatically yield enormous market returns and investment returns." 技术之外，资本市场真正在寻找的另有答案。 Beyond technology, what the capital market is truly seeking lies in another answer. 02 企业家精神的底色 The Essence of Entrepreneurship 资本市场逐利而动，但高收益往往伴随高风险，二者互为表里，无法剥离。那些能将技术转化为可持续商业价值的人，往往更加懂得如何驾驭风险。因此一个能真正穿越周期的领创者，必须具备超越技术本身的企业家精神。 The capital market moves in pursuit of profit, but high returns often accompany high risks; the two are the outward and inward aspects of the same entity, inseparable. Those who can transform technology into sustainable commercial value typically understand even better how to manage risk. Therefore, a pioneer innovator who can truly traverse cycles must possess an entrepreneurial spirit that transcends technology itself. 王昕认为："企业家精神不是体现在他能研发出一个好的产品，而是在于整合资源的能力。" Dr. Neil Wang believes: "Entrepreneurial spirit is not manifested in one's ability to develop a good product, but rather in the capacity to integrate resources." 优秀的企业家必须有办法充分利用所有的社会资源和商业生态资源，把不同的利益相关者整合起来组成一个团队。这个团队不光指企业内部团队，王昕说："外面的世界非常广阔，如果一个企业家能发动外部的社会资源，让商业合作伙伴、生态，甚至政府职能部门、政策制定方、监管机构都能支持他，重视他的一些理念、产品、服务，乃至他的市场进入策略、营销布局和全球化战略，那么企业的价值就更容易被广泛看见与认同。" An outstanding entrepreneur must find ways to fully utilize all social resources and commercial ecosystem resources, integrating different stakeholders to form a team. This team does not refer only to the internal enterprise team, Dr. Neil Wang said: "The outside world is extraordinarily vast. If an entrepreneur can mobilize external social resources, enabling commercial partners, the ecosystem, and even government functional departments, policymakers, and regulatory agencies to support him and attach importance to his concepts, products, services, as well as his market entry strategies, marketing layouts, and globalization strategies, then the value of the enterprise will more easily be widely seen and recognized." 2026福布斯中国行业发展领创者评选颁奖盛典上，沙利文特意邀请了产、学、研、投、媒各界人士齐聚活动现场，对企业家而言，这正是一次难得的资源整合与生态链接机会。 At 2026 Forbes China Pioneer Innovators in Industry Development Selection Gala Banquet, Frost & Sullivan deliberately invited figures from industry, academia, research, investment, and media to gather at the event. For entrepreneurs, this was precisely a rare opportunity for resource integration and ecosystem linkage. 王昕所说的"外面的世界"是要放眼全球。他说："现在的竞争，是地球村里的竞争。竞争的国际属性，我们绝对不能遗忘。" The "outside world" that Dr. Neil Wang spoke of requires a global perspective. He said: "Today's competition is competition within the global village. The international nature of competition is something we must never forget." 他讲了一个真实的故事，一位百亿级上市公司的企业家说要出海，专家问："你要去哪个国家？"企业家说："我要去非洲。"专家又问："非洲有五十几个国家，你想去哪个？语言、文化、开放程度、经济发展水平千差万别。你都不知道自己在问什么，又何谈答案？" He told a true story. An entrepreneur from a listed company with a market value in the tens of billions said he wanted to go overseas. An expert asked: "Which country do you want to go to?" The entrepreneur replied: "I want to go to Africa." The expert asked again: "There are over fifty countries in Africa. Which one do you want to go to? The languages, cultures, levels of openness, and economic development vary enormously. You don't even know what you're asking, so how can you talk about answers?" 王昕很清楚，企业家并不是全能的，尤其是在全球化这门复杂的功课面前，没有人是天生的优等生。但这没关系，沙利文可以提供系统的方法论。近期，沙利文和中国顶级的出版社达成合作，即将推出一本《企业出海增长指南》（英文名为《GO GLOBAL: The Growth Coaching Book》）。他相信，全球化的势头，没有任何人可以阻挡。 Dr. Neil Wang is well aware that entrepreneurs are not omnipotent, and especially before the complex subject of globalization, no one is a born top student. But that is all right; Frost & Sullivan can provide systematic methodologies. Recently, Frost & Sullivan has reached a cooperation with a top-tier Chinese publisher and will soon launch a book titled "企业出海增长指南" (with the English title "GO GLOBAL: The Growth Coaching Book"). He believes that the momentum of globalization is unstoppable by anyone. 他形象地介绍："出海，就好像坐船。你不可能开个小舢板出海，可能没开出几公里，一个浪来了就翻了。一定要有海图告诉你哪里有暗礁，有GPS帮你做引导。这不是盲人摸象，而是要有既定的步骤、有全球通行的成熟方法。" He vividly explained: "Going overseas is like sailing. You cannot set out to sea in a small sampan; you might not get a few kilometers before a wave capsizes you. You must have nautical charts to tell you where the reefs are, and GPS to guide you. This is not groping about in the dark like a blind man touching an elephant, but rather having established approaches and mature methodologies recognized globally." 他对沙利文很有信心，因为用专业为企业赋能这件事，沙利文已经做了65年。 He has great confidence in Frost & Sullivan, because empowering enterprises with professionalism is something Frost & Sullivan has been doing for 65 years. 03 65年浇灌信任 65 Years of Nurturing Trust 咨询行业潮起潮落，每10-20年就会迎来一次格局洗牌，而沙利文是全球少有的、横跨半个多世纪仍保持活跃的专业咨询机构之一。 The consulting industry ebbs and flows, with its landscape reshuffled every 10 to 20 years. Frost & Sullivan is one of the few professional consulting institutions globally that has remained proactive across more than half a century. 目前，沙利文在全球设有近50个分支机构，覆盖所有的发达国家、新兴经济体和主要资本市场，成为无数客户的信赖之选。信任，是它的王牌。 Currently, Frost & Sullivan has nearly 50 branches worldwide, covering all developed countries, emerging economies, and major capital markets, becoming the trusted choice of countless clients. Trust is its trump card. "现在海量信息鱼目混珠，良莠不齐。获取信息的成本极大下降了，但质量也打上了问号。"王昕说，"水军、假新闻、AI伪造的内容、不良个体或小机构的短期行为……它们没有历史沿革，没有长期经营的观念，不把品牌和质量放在第一位。所以，信任是普遍匮乏的。" "Now, massive amounts of information are a mix of fish eyes and pearls, of uneven quality. The cost of obtaining information has dropped enormously, but its quality is also cast into doubt," Dr. Neil Wang said. "Internet water armies, fake news, AI-generated forgeries, short-term behavior by unscrupulous individuals or small institutions... they have no historical lineage, no concept of long-term operation, and do not place brand and quality first. Therefore, trust is universally scarce." 沙利文成立65周年的关键词就选定为"信任"，王昕时常提醒团队，脚踏实地地认真做好每一天的本职工作，慢工出细活，不能追求一蹴而就。 The keyword chosen for Frost & Sullivan's 65th anniversary is "Trust." Dr. Neil Wang frequently reminds his team to do their daily work conscientiously and steadily, with the understanding that slow and careful work yields fine results, and that one cannot pursue instant success. 他阐释，沙利文从三个层面构建信任：第一，提供可信的方法论，一套被绝大多数各方接受的标准操作流程，与全球标准对齐的正规度；第二，是历史沿革，65年来公司保持了良好的业界口碑，在全球覆盖数百个细分行业，通过持续研究形成数据库、行业知识库，确保信息的准确性；第三，只选择顶级合作伙伴。与福布斯中国联合主办的行业发展领创者评选即是诞生于这样的标准。 He elaborated that Frost & Sullivan builds trust on three levels: first, by providing credible methodologies—a set of standard operating procedures accepted by the vast majority of parties, with a degree of formality aligned with global standards; second, through historical lineage—over 65 years, the company has maintained an excellent industry reputation, covering hundreds of niche industries globally, and through sustained research has formed databases and industry knowledge bases to ensure information accuracy; third, by selecting only top-tier partners. the Awards of Pioneer Innovators in Industry Development co-hosted with Forbes China were born from such standards. 正是这种坚持，让沙利文的报告获得全球主要机构的普遍认可。王昕说："在常年扮演独家IPO行业顾问的过程中，我们的研究结论需要进入招股说明书，持续接受监管机构、投资者和市场的多重审视。近10年来，沙利文连年蝉联中国企业赴香港及境外上市专业行业顾问市场份额的领导地位。2025年沙利文香港IPO行业顾问市占率高达73%。这种高度集中的市场认可本身就是一种信任机制。" It is precisely this persistence that has won Frost & Sullivan's reports widespread recognition from major institutions worldwide. Dr. Neil Wang said: "In the process of serving as an exclusive IPO industry advisor over the years, our research conclusions must enter prospectuses and continuously undergo multiple scrutiny by regulators, investors, and the market. Over the past decade, Frost & Sullivan has consecutively maintained its leadership in market share as the professional industry advisor for Chinese enterprises listing in Hong Kong and overseas. In 2025, Frost & Sullivan's market share as a Hong Kong IPO industry advisor reached as high as 73%. This highly concentrated market recognition is itself a mechanism of trust." 沙利文追求长期主义，对前沿科技的追踪同样遵循这套系统性的方法论。面对AI浪潮，早在七八年前创办头豹科创网时，王昕就前瞻性地提出了"AI+HI"（人工智能+人类智能）的理念，并且一直身体力行。 Frost & Sullivan pursues long-termism, and its tracking of cutting-edge technology similarly follows this systematic methodology. Faced with the AI wave, as early as seven or eight years ago when founding LeadLeo Science and Technology Innovation Network, Dr. Neil Wang put forward the forward-looking concept of "AI + HI" (Artificial Intelligence + Human Intelligence) and has consistently practiced it. "AI可以进行海量数据的处理，可以在人的指挥下筛选出数学模型，这是人力所不及的。"他解释，"就好像我们去拔草，用手能拔几根？但开着除草机去，效率就高了。不是我们人不行，而是我们把不擅长的工作，交给了擅长做这些工作的AI。" "AI can process massive amounts of data and, under human direction, screen out mathematical models—this is beyond human capability," he explained. "It is like weeding: how many weeds can you pull by hand? But drive a weeding machine, and efficiency soars. It is not that we humans are incapable, but rather that we entrust tasks we are not good at to AI, which excels at them." 他话锋一转："AI是有短板的。比如，见一叶落而知天下秋，机器看到一片叶子掉了，它不知道这意味着什么。再比如，一个苹果砸在牛顿头上，和砸在普通人头上，是两个效果。" He then shifted his tone: "AI has its shortcomings. For example, when one leaf falls, the wise know that autumn is coming; when a machine sees a leaf drop, it does not know what it means. Another example: an apple falling on Newton's head and an apple falling on an ordinary person's head produce two entirely different effects." 所以在沙利文，AI提供效率和广度，人提供深度和判断。两者结合，才能输出真正值得信任的结论。 Therefore, at Frost & Sullivan, AI provides efficiency and breadth, while humans provide depth and judgment. Only by combining the two can truly trustworthy conclusions be delivered. 他的技术理念与当前中国的人工智能发展战略部署同频共振。在中国，沙利文已经连续经营28年。它始终坚持高度本土化，以服务国家与社会、推动经济发展、增进人民福祉，为经营宗旨。积极响应中国的产业政策和战略转型方向，在"一带一路"、双循环、双碳、企业出海、品牌强国、数字中国等重大战略布局上，贡献行业力量。 His technological philosophy resonates in frequency with China's current AI development strategy and deployment. In China, Frost & Sullivan has operated continuously for 28 years. It has consistently adhered to a high degree of localization, with its operational mission being to serve the nation and society, promote economic development, and enhance the well-being of the people. It actively responds to China's industrial policies and strategic transformation directions, contributing industry strength to major strategic layouts such as the Belt and Road Initiative, dual circulation, dual carbon, enterprise globalization, brand empowerment, and Digital China. 王昕相信："未来我们可以发挥的空间非常巨大。"因为这家走过65载春秋的公司，步履轻快，对未来依然充满好奇，"影响世界的50大科技"、"中国未来50年"……沙利文从未停止向读者分享眺望未来的目光。 Dr. Neil Wang believes: "The space in which we can exert influence in the future is enormously vast." Because this company, having traversed 65 years, moves with light steps and remains full of curiosity about the future—"Top 50 Technologies Shaping the World," "China's Next 50 Years"... Frost & Sullivan has never stopped sharing its gaze toward the future with its readers. 这或许就是"信任"二字在这个时代最稀缺、也最珍贵的含义：它不是一句口号，而是一个在长期稳定的坚持中，一点点积累起来的、可验证的承诺。它来自于对互利共赢的践行，对民众福祉的关切，也来自于对长期主义的信仰。 This, perhaps, is the most scarce and most precious meaning of the word "trust" in this era: it is not a slogan, but a verifiable promise accumulated bit by bit through long-term, steadfast persistence. It comes from the practice of mutual benefit and win-win outcomes, from concern for the well-being of the people, and from faith in long-termism. 无论是领创者，还是托举者，最终都要回归到这个朴素却颠扑不破的真理上来。 Whether pioneer innovators or those who support them, all must ultimately return to this simple yet indestructible truth. 本文版权归福布斯所有，经授权转载

stand "At the new starting point of the 15th Five-Year Plan," 2026 The 'Annual Government Work Report' clearly states that it is necessary to cultivate and strengthen emerging and future industries, and promote industries such as biomanufacturing to become new economic growth points. Synthetic biology, as follows DNA The discovery of the double helix structure “and the third life science revolution following the “Genomic Technology Revolution” are leading the biomanufacturing industry into accelerated advancement 4.0 The era has become an important strategic fulcrum for reshaping the global material production mode. In the future, it will deeply reconstruct the development paradigms of industries such as biomedicine, advanced materials, consumer goods, energy, environmental protection, and agriculture. Vigorously developing synthetic biology and bio-manufacturing industries is not only a strategic opportunity to seize the global high ground but also an important path to accelerate the formation of new productive forces and achieve high-level scientific and technological self-reliance. Based on its long-term insight into the global cutting-edge technology and biomanufacturing industries, Frost & Sullivan frost  & Sullivan Frost & Sullivan, hereinafter referred to as 'Frost & Sullivan'), will launch the Global Synthetic Biology and Bio-manufacturing Industry Development White Paper ( 2026 The preparation and compilation of the white paper. This white paper will cover “government - give birth - learn - research - gold - The close collaboration and in-depth research results presented in this report aim to provide forward-looking structured insights and references for government agencies, investment institutions, industry sectors, and all sectors of society. Research content This white paper systematically reviews the global development landscape of synthetic biology and biomanufacturing industries. Through a detailed industrial chain map, it deeply analyzes the current development status of upstream tool layers, midstream platform layers, and downstream diversified application scenarios. From dimensions such as technological evolution, business logic, and market structure, it elucidates the strategic value of synthetic biology in reconstructing production logic, ensuring supply chain security, and driving green sustainable development.   In addition, we will focus on sorting out the industrial ecosystems and regulatory frameworks of major global countries such as China and the United States, comparing the differences in industrial ecosystems and development stages under different policy environments, and analyzing The synergistic relationship between 'regulatory innovation' and 'industry source development' includes promoting green and low-carbon transformation, ensuring supply chain security, and reshaping the industrial landscape. At the same time, the report will systematically deconstruct the development stage and industrial structure characteristics of the industry in light of the actual development situation of the Chinese market, and deeply explore the core driving forces behind the future leapfrog development of China's synthetic biology and biomanufacturing industries, so as to gain insights into future development trends.   Among them, for the chapters on upstream and downstream of the industrial chain, benchmark cases (parks, enterprises, industrial platforms, etc.), we sincerely invite relevant enterprises to cooperate. By sharing their first-person perspectives on how to face existing challenges and seize business opportunities, enterprises can showcase their core competitiveness such as business models, technology platforms, advanced processes, and ecological cooperation. These empirical cases will provide authoritative voices and focused dissemination windows for cooperative enterprises, as well as references for capital providers, research institutions, industries, etc., attracting upstream and downstream partners to actively join the enterprise ecosystem. Participating in the cooperation of this white paper will help enhance the brand voice of cooperative enterprises in the global market and assist in global brand building and product layout. Enterprise participation value   1. Global brand voice building and authoritative endorsement   The English version of the white paper will be made available simultaneously on well-known global news agencies (such as The Associated Press), mainstream financial media (such as Yahoo Finance), North American financial media and websites (Business Insider, Dow Jones MarketWatch, Benzinga, Wall Street Insider, etc.) and media from various regions around the world.   Relying on Frost & Sullivan's global media matrix and brand influence, the company will enhance its strategic position in the global synthetic biology and biomanufacturing sectors, helping to build brand influence and business credibility for the international market.   2. Establishing industry image and industry discourse power   This white paper will deeply integrate enterprise market research, technical insights, and industry practice cases. Relying on systematic and professional research results, it will help enterprises consolidate their professional image and strategic positioning in niche markets, highlight their leading edge in technology understanding, enhance their professional recognition and voice, and improve their visibility and influence within the industry and external markets.   3. Empowering ecological connectivity and capital value transmission   The white paper will serve as a core link connecting the industrial end and the capital end, accurately reaching investors in the primary and secondary markets, relevant government agencies, and upstream and downstream partners of the industrial chain. By deeply analyzing a company's business layout and core capabilities, it transforms the company's business potential into a 'logical language' understandable by the capital market, creating a high-value foundation for subsequent investment and financing matchmaking, government resource implementation, and strategic cooperation. White Paper Release Schedule   Project start time      : May 2026   The full report is now available.      : 2026 Global Growth, Innovation & Leadership Summit by Frost & Sullivan and the 5th New Investment Conference, August 4-5, 2026   Release channel   The Frost & Sullivan group has a creative matrix comprising over 30 financial platforms and financial media, operating accounts including Frost & Sullivan, LeadLeo, LiveReport (a big data platform), and more. The network has over 500,000 highly knowledgeable and affluent fans composed of investors, analysts, entrepreneurs, media professionals, and more.   Participate in cooperation     Please contact us     Frost & Sullivan China   Senior Partner and Managing Director   Yang Xiaocheng   Email: jacky.yang@frostchina.com   Frost & Sullivan China   Chief Medical Analyst   Sun Rong   Email: skyler.sun@frostchina.com   Long press to scan the QR code below, and we will contact you.

Exclusive Interview with Frost & Sullivan Entrepreneurs   True Biology was established in In 2012, the company was a biotechnology enterprise driven by innovative research and development, focusing on the development, production, and commercialization of innovative drugs for major diseases such as viral infections and tumors. The company adheres to the orientation of meeting unmet clinical needs, concentrates on the fields of antiviral and anti-tumor research, and is committed to addressing key challenges such as drug resistance and insufficient efficacy through mechanism innovation. The company's core management team has rich experience in international innovative drug research and development and transformation, providing solid support for continuous innovation.   In the field of viral infections, the company's core product Azvudine has been conditionally approved for use HIV infection and COVID-19 treatment, with the latter becoming the first domestically approved oral drug in this field. Moreover, Azvudine, with its dual mechanism of 'inhibiting viral replication + immune regulation,' shows potential clinical value in areas where immunological recovery is incomplete. The ongoing product CL-197 has long-acting characteristics and is expected to achieve once-weekly dosing, improving treatment compliance.   In the oncology field, the company has expanded its antitumor indications around AZD9291 and is advancing its collaboration with The development of PD-1 monoclonal antibody combination therapies aims to break through the limitations of current immunotherapy. In addition, the company is simultaneously deploying innovative directions such as non-camptothecin structure TOPO1 inhibitors, ADCs, and peptide radioconjugated drugs (PRCs), developing unique drug pipelines targeting tumor resistance and heterogeneity.   Real Biotech has established a complete production and commercialization system, with core products achieving wide terminal coverage. In the future, the company will continue to advance the development of innovative pipelines to enhance clinical value and accessibility.   Against this backdrop, Frost & Sullivan frost  & Frost & Sullivan, hereinafter referred to as 'Frost & Sullivan', invited Dr. Du Jinfan, Chairman, CEO and CSO of Zhenre Biology, to participate in a dialogue and exchange, focusing on the company's R&D strategy and product layout. Exclusive Interview Guest       PROFILE   · Dr. Du Jinfa   · Chairman of Real Biotech   · CEO and CSO · Recognized by the Chinese government "National Distinguished Expert"   One of the inventors of the revolutionary hepatitis C treatment drug sofosbuvir   The drug has been hailed as The Galen Prize, known as the 'Medicine Nobel Prize'.   The contribution to the treatment of hepatitis C has been hailed by the journal Cell as one of the most significant public health achievements of our time. 01 Focus on unmet clinical needs and build an innovative R&D system driven by both antiviral and anti-tumor strategies @Frost & Sullivan China Healthcare Business Unit     In your previous career, you have been involved in the research and development of key drugs for AIDS treatment - Enquetiapine, this drug is still one of the main medications used for treating AIDS patients globally. Later, the hepatitis C cure drug sofosbuvir was developed, creating significant social and economic benefits. Looking back on this experience, what is your deepest takeaway? How have these experiences influenced your return to China?    @Dr. Du Jinfang   The most profound realization is that when making medicine, one must create products that can truly address unmet clinical needs and benefit human health. This cannot be achieved without genuine pharmaceutical innovation. Innovation requires the courage to be ahead of others and to venture into uncharted territories.   Challenging the impossible has always been a core aspect of my new drug research and development practice. At Zai Lab, before embarking on each project, we ask: What is the most troubling issue for patients in this field, and how do we solve it? Therefore, in response to unmet clinical needs, we have deployed a series of unique drug pipelines.   @Frost & Sullivan China Healthcare Business Unit     Real Biotech has long focused on antiviral and anti-tumor fields. Could you please share the company's core judgments on research and development direction choices? How does the company identify tracks with truly unmet clinical needs? Additionally, the company has established nucleoside drugs, The TOPO1 inhibitor and XDC, as well as other diversified R&D platforms, how do these platforms collaborate with each other, and what key roles have they played in enhancing the overall R&D success rate?    @Dr. Du Jinfang   Real Biotech focuses on the fields of antiviral and anti-tumor research, with R&D directions centered on unmet clinical needs. It prioritizes the layout of disease tracks with high disease burden, prominent drug resistance issues, and existing therapeutic bottlenecks, focusing on solving key pain points that have not been met clinically.   Among them, the nucleoside platform serves as the underlying core, fully exploring the value of Azvudine in anti-infection and anti-tumor applications, focusing on unmet clinical challenges such as immune reconstruction deficiency and immunosuppression.   New non-hypogalatinizing agents TOPO1 Inhibitor platform, overcoming traditional toxin resistance from the source, available as a monotherapy or as part of a new generation ADC high activity toxin;   XDC Dual load platform layout ADCs coupled with peptide radionuclides (PRCs) target innovative targets that have not yet been addressed by drugs in the oncology field, offering innovative solutions for tumor heterogeneity and resistance development.   The three major platforms form a collaborative R&D pattern through underlying technology interoperability, complementary mechanisms, and resource sharing, providing continuous support for the company's long-term innovative development. 02 Deepen antiviral strategies, expand on immune reconstruction deficits The therapeutic value of INR) and leads the innovative direction of long-acting HIV   @Frost & Sullivan China Healthcare Business Unit     Azvudine, the core product of the company, has been commercially launched in the field of antiviral therapy and has accumulated relatively sufficient data in clinical trials and real-world settings. How do you evaluate its clinical value and competitive advantage within the current treatment system?    @Dr. Du Jinfang   Azvudine, with its low dose, high activity, dual target, and immunomodulatory comprehensive characteristics, The HIV treatment system has unique advantages and broad clinical value.   Clinical trial data shows, Azvudine 3 mg has an antiviral effect comparable to lamivudine 300 mg, achieving effective viral suppression at a low dose. At the same time, the drug has dual targets to inhibit viral replication. + The unique mechanisms of immunomodulation not only enrich existing treatment options but also The global unmet need for HIV immune reconstitution provides an important research direction and potential solutions.   @Frost & Sullivan China Healthcare Business Unit     Why do real organisms focus on immune reconstitution insufficiency? Regarding the issue of (INR), how do you view the clinical value and future treatment directions in this field?    @Dr. Du Jinfang   Immunodeficiency INR is a globally recognized clinical challenge in the field of HIV treatment, with significant unmet needs.   According to the 'Guidelines for the Diagnosis and Treatment of AIDS in China ( (2024 Edition). After ART treatment, the immune abnormalities of some patients can return to normal or near-normal levels, achieving immune function reconstruction. However, there are still 10% to 40% of patients who cannot fully achieve immune reconstruction even after long-term viral suppression. Compared with those who have achieved complete immune reconstruction, these patients have a higher incidence and mortality rates of opportunistic infections, non-AIDS complications, tumors, etc. Currently, there is a global lack of effective treatment drugs for patients with incomplete immune function reconstruction, and there is an urgent unmet clinical need.   Related work has been carried out by real organisms According to IIT research, positive data were observed in subjects after treatment with Azvudine, which will be further validated through larger-scale clinical studies, aiming to provide new treatment pathways for this field.   03 Give full play to the advantages of dual mechanisms, promote combined immunotherapy, and expand the space for tumor indications   @Frost & Sullivan China Healthcare Business Unit     Azvudine has expanded its application scope from the field of anti-infection to anti-tumor therapy, How does the 'dual mechanism' play a role in tumor treatment? What are its unique advantages?    @Dr. Du Jinfang   Azvudine passes "Direct tumor suppression + immune regulation The dual mechanism exerts a broad-spectrum anti-tumor effect. On one hand, azvudine can terminate DNA chain elongation and interfere with the function of enzymes related to cancer cell nucleic acid synthesis, directly inhibiting tumor cell proliferation. On the other hand, it can reduce the infiltration of myeloid-derived suppressor cells (MDSCs) in the tumor microenvironment and promote CD8⁺ T cells, CD4⁺ T   Cell infiltration and proliferation reshape the immunosuppressive microenvironment, activating the body's own anti-tumor immune response.   Compared with anti-tumor drugs that rely solely on a single mechanism, azvudine combination therapy can achieve The synergistic effect of '1+1>2' can particularly transform 'cold tumors' into 'hot tumors', breaking through the bottlenecks of immune therapy resistance and non-response, and possesses significant differential advantages in the treatment of broad-spectrum solid tumors.   @Frost & Sullivan China Healthcare Business Unit     this year In February, the clinical trial of azvudine combined with PD-1 monoclonal antibody for the treatment of advanced solid tumors was approved by the National Medical Products Administration. What are the core considerations behind the company's decision to advance this combination therapy? How do you evaluate the potential for this combination regimen to be applied in a broader patient population?    @Dr. Du Jinfang   Our choice for this direction is mainly aimed at breaking through the current clinical bottlenecks in immunotherapy. Taking colorectal cancer as an example, there are approximately RMB 2.03 million, of which approximately 95% are microsatellite-stabilizing (MSS) patients. These patients are basically ineffective with PD-1 monotherapy and face the dilemma of having no effective immunotherapy options for a long time.   A clinical trial initiated by a researcher has shown that azvudine in combination PD-1 inhibitors and anti-VEGFR drugs are used for patients with microsatellite stable colorectal cancer who have received multiple lines of treatment: In the non-liver metastasis subgroup, the disease control rate was 100% in the higher dose group, the objective response rate was 40%, and the average treatment duration reached 33.9 weeks, showing positive data in terms of clinical efficacy and treatment persistence.   Based on clear mechanism synergy and positivity IIT data suggests that this combined approach holds promise for transforming 'cold tumors' into 'hot tumors', breaking through the immune treatment bottleneck for refractory tumors such as MSS colorectal cancer, and has significant application potential in a broader population of patients with advanced solid tumors.   04 Focusing on the challenges of drug resistance and heterogeneity, we are building a diversified conjugation and small molecule innovation platform   @Frost & Sullivan China Healthcare Business Unit     company The TOP1 inhibitor platform adopts a non-camptothecin structure and has an advantage in overcoming drug resistance. What is your view on the strategic significance of this platform in next-generation anti-tumor drugs?    @Dr. Du Jinfang   Currently exceeds Eighty percent of ADC drugs use taxanes as their toxins, and most of these drugs develop resistance after a period of treatment. We aim to develop a drug with a completely new chemical structure to provide an effective solution for this type of drug-resistant tumor.   Preclinical research results indicate that the new Topo1 inhibitor, ZSSW-136, has an inhibitory activity against drug-resistant tumors that is 400 times greater than that of irinotecan in patient-derived xenografts. In animal models of drug-resistant tumors, it can completely inhibit tumor growth. The results of this study are currently being published. Notably, it can be used alone as a small molecule compound for drug development or as the toxin of a new generation of ADCs, leading to the development of a series of novel ADCs antitumor drugs effective against existing ADC-resistant tumors.   @Frost & Sullivan China Healthcare Business Unit     In the field of novel conjugated drugs, the company has made arrangements In the ADC and PRC directions, such as PSMA dual payload ADCs and GRPR-targeted PRC pipelines. Why did the company choose these two targets?    @Dr. Du Jinfang   The company's layout in the field of novel conjugated drugs always focuses on innovative targets that have not yet been addressed in oncology, aiming to meet unmet clinical needs and develop innovative solutions for the challenges of tumor heterogeneity and resistance.   Among them, PSMA is a validated antigen with high tumor specificity, limited expression in normal tissues, and efficient internalization capabilities. Based on the characteristics of this target, ZS-1005, a dual payload ADC candidate drug with an innovative mechanism, has been designed by Zhenbio. It currently exhibits excellent tumor growth inhibitory capabilities and good safety profiles in mouse models of prostate cancer and other diseases.   and GRPR is expressed at low levels and in limited distribution in normal tissues, but it is highly expressed in various human solid tumors including lung cancer, breast cancer, prostate cancer, some gastrointestinal tumors, and neuroblastoma. It may be involved in promoting tumor growth and progression, making it a highly promising therapeutic target. Our candidate drug ZS-2004, developed based on this target, has observed excellent efficacy and safety data in animal trials and is currently undergoing further preclinical studies.   @Frost & Sullivan China Healthcare Business Unit     real organisms What are the core technical advantages of ADC 'Dual Payload' design? What specific value can it bring to clinical practice?    @Dr. Du Jinfang   Dual payload design is a key technological innovation for real organisms to cope with tumor heterogeneity and resistance risks. In the ADC field, this design achieves simultaneous killing of tumor cells in different cell cycles by precisely delivering two toxins with different mechanisms of action to tumor cells. It also takes into account antigen-expressing and antigen-lowly expressing subpopulations, effectively addressing the challenges posed by tumor heterogeneity.   At the same time, this strategy can delay or overcome the risk of single pathway resistance at the source. The synergy of these two mechanisms is expected to enhance the therapeutic index and safety margin, providing a more durable response for clinical practice. This design aims to ensure the effectiveness and safety of treatment, further improving long-term benefits for patients.   05 From product commercialization to industry evolution, gain insights into future technology trends and competitive landscape   @Frost & Sullivan China Healthcare Business Unit     From a commercialization perspective, what do you believe are the company's most core strengths in terms of production capacity, access, and channels? Especially against the backdrop of the gradual advancement of Azvudine's new indications, how will these strengths be translated into future growth drivers?    @Dr. Du Jinfang   From a commercialization perspective, the company has established an integrated, replicable, and rapidly scalable commercial support system across three major sectors: production capacity, access channels, and distribution networks. This can provide a stable guarantee for the long-term development of Azvudine and the company's overall innovation pipeline.   Firstly, there is guaranteed self-production capacity through scale-up and compliance. The company has completed GMP Certify a modern production base with stable and large-scale supply capabilities, capable of supporting the sales of existing indications and rapid expansion of new indications in the future. Ensure that supply, quality, and costs are controllable.   Secondly, the medical insurance access and price advantage are prominent. Azvudine has been included in the national medical insurance catalog, with stable prices and significant policy and cost advantages. This enhances the accessibility of the drug, laying the foundation for its rapid hospitalization and increased usage in new indications.   Thirdly, in terms of channels and commercialization capabilities, the company has established a commercial network covering medical institutions nationwide, off-campus platforms, and online platforms. It has also assembled a professional team with relevant experience, capable of providing implementation and promotion support for more innovative products based on AZD307.   At the same time, Zhenre Biology adheres to its commercial strategy of 'rooted in China, radiating globally'. Focusing on the global layout of Azvudine, it targets advantageous markets such as Africa, Southeast Asia, Europe, and America. Through localized cooperation and rapid registration, it achieves overseas presence, expands cross-regional revenue sources, and ensures sustainable profitability. Subsequently, with the clinical breakthrough of Azvudine in new indications such as tumors, combined with the cooperation and expansion of innovative pipelines such as ADCs, PRCs, and TOPO1 inhibitors, it further opens up larger market spaces, forming a matrix of core product iteration + innovative pipeline, serving as a long-term growth engine through collaboration.